Fennec Pharmaceuticals Inc.: shareholders and insiders

FENCNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$13.33

November 18, 2026Market cap $460M

What Ploutos Investor adds for Fennec Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 14 fiscal years, from 2011
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has risen 22% since Nov 12, 2026, when the 10-Q these figures come from was filed ($10.90 then, $13.33 on Nov 18, 2026). The figures date from before that move.10-Q
  • The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.
  • Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.

Insiders and their shares

Purchases and sales by officers and directors from Nov 19, 2025 to Nov 16, 2026, from their own Form 4 filings.

47 Form 4s

Insider trades start on May 2, 2007

Until lately Fennec Pharmaceuticals was a foreign company listed in the US. Officers of foreign companies do not report their purchases and sales, so there are none before. They are not missing on our side: they were never filed.

  1. Until 2007Foreign company (annual report on 20-F)
  2. March 2008Becomes a US filer (annual report on 10-K)
  3. May 2, 2007The first insider trade report (Form 4)

Bought on the market

–

nobody

Sold on the market

$9.9M

6 people

From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan22%
  • The rest78%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $2.3M by 5 people

  • 2025: no buys, sold $7.6M by 2 people
  • 2026: no buys, sold $2.3M by 5 people
  • Nov 13, 2026Marco Maria BrugheraDirector
    Kind10b5-1
  • Nov 13, 2026Marco Maria BrugheraDirector
    Kind10b5-1
  • Oct 31, 2026Terry L EvansChief Commercial Officer
    Kind
  • Oct 31, 2026Pierre Sargis SayadChief Medical Officer
    Kind
  • Oct 31, 2026Jeffrey S. HackmanChief Executive Officer
    Kind
  • Oct 31, 2026Christiana Marie CioffiChief Strategy Officer
    Kind
  • Oct 31, 2026Robert AndradeCHIEF FINANCIAL OFFICER
    Kind
  • Oct 12, 2026Pierre Sargis SayadChief Medical Officer
    Kind
  • Oct 12, 2026Jeffrey S. HackmanChief Executive Officer
    Kind
  • Oct 12, 2026Terry L EvansChief Commercial Officer
    Kind
  • Oct 12, 2026Christiana Marie CioffiChief Strategy Officer
    Kind
  • Oct 12, 2026Robert AndradeCHIEF FINANCIAL OFFICER
    Kind
  • Sep 30, 2026Pierre Sargis SayadChief Medical Officer
    Kind
  • Sep 30, 2026Terry L EvansChief Commercial Officer
    Kind
  • Sep 30, 2026Jeffrey S. HackmanChief Executive Officer
    Kind
  • Sep 30, 2026Christiana Marie CioffiChief Strategy Officer
    Kind
  • Sep 30, 2026Robert AndradeCHIEF FINANCIAL OFFICER
    Kind
  • Sep 15, 2026Marco Maria BrugheraDirector
    Kind10b5-1
  • Sep 15, 2026Marco Maria BrugheraDirector
    Kind10b5-1
  • Sep 1, 2026Rosty Raykov
    Kind10b5-1
  • Aug 31, 2026Rosty Raykov
    Kind10b5-1
  • Aug 31, 2026Pierre Sargis SayadChief Medical Officer
    Kind
  • Aug 31, 2026Pierre Sargis SayadChief Medical Officer
    Kind
  • Aug 31, 2026Terry L EvansChief Commercial Officer
    Kind
  • Aug 31, 2026Christiana Marie CioffiChief Strategy Officer
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 1, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by FENC's officers and directors from 2010 up to November 18, 2025, 16 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

4 Holders over 5%Oct 19, 2026 Latest filing
  • Rosalind Advisors, Inc.with 3 more personsCommon Shares
    Share of class9.60%
  • Sonic Fund II, L.P.with 2 more persons
    Share of class8.20%
  • Orin Hirschmanwith 1 more personCommon Shares, no par value
    Share of class7.10%
  • Solas Capital Management, LLCwith 1 more personCommon Shares, no par value
    Share of class5.40%
Fell to 5% or less (2)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • Southpoint Master Fund, LP0.00%Aug 14, 202613G/A
  • DG Capital Management, LLC4.10%Feb 14, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Point72 (Cohen)
    In the quarter-41%
  • Citadel Advisors (Griffin)
    In the quarter+133%
  • Millennium Mgmt (Englander)
    In the quarter+41%
  • Renaissance Technologies
    In the quarter+2.4%
  • AQR Capital
    In the quarter+1.0%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 1.41% of its shares outstanding were held short, -5.0% since the report before.

Shares held short
487.5K
1.41%
Since the report before513.3K on Sep 30, 2026
-5.0%
3.8
129.1K
More days to cover thanof 4,578 US-listed companies with enough volume
45%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 1.92M
  • Nov 15, 2023: Shares held short 1.96M
  • Nov 30, 2023: Shares held short 1.91M
  • Dec 15, 2023: Shares held short 2.04M
  • Dec 29, 2023: Shares held short 2.01M
  • Jan 12, 2024: Shares held short 1.86M
  • Jan 31, 2024: Shares held short 1.79M
  • Feb 15, 2024: Shares held short 1.75M
  • Feb 29, 2024: Shares held short 1.71M
  • Mar 15, 2024: Shares held short 1.69M
  • Mar 28, 2024: Shares held short 1.81M
  • Apr 15, 2024: Shares held short 1.87M
  • Apr 30, 2024: Shares held short 1.81M
  • May 15, 2024: Shares held short 1.74M
  • May 31, 2024: Shares held short 1.77M
  • Jun 14, 2024: Shares held short 1.77M
  • Jun 28, 2024: Shares held short 1.80M
  • Jul 15, 2024: Shares held short 1.95M
  • Jul 31, 2024: Shares held short 1.94M
  • Aug 15, 2024: Shares held short 1.91M
  • Aug 30, 2024: Shares held short 1.84M
  • Sep 13, 2024: Shares held short 1.84M
  • Sep 30, 2024: Shares held short 1.85M
  • Oct 15, 2024: Shares held short 1.84M
  • Oct 31, 2024: Shares held short 1.78M
  • Nov 15, 2024: Shares held short 1.87M
  • Nov 29, 2024: Shares held short 2.10M
  • Dec 13, 2024: Shares held short 2.11M
  • Dec 31, 2024: Shares held short 1.98M
  • Jan 15, 2025: Shares held short 2.00M
  • Jan 31, 2025: Shares held short 1.95M
  • Feb 14, 2025: Shares held short 2.04M
  • Feb 28, 2025: Shares held short 1.93M
  • Mar 14, 2025: Shares held short 1.44M
  • Mar 31, 2025: Shares held short 1.50M
  • Apr 15, 2025: Shares held short 1.44M
  • Apr 30, 2025: Shares held short 1.45M
  • May 15, 2025: Shares held short 1.51M
  • May 30, 2025: Shares held short 1.42M
  • Jun 13, 2025: Shares held short 1.36M
  • Jun 30, 2025: Shares held short 1.31M
  • Jul 15, 2025: Shares held short 1.30M
  • Jul 31, 2025: Shares held short 1.28M
  • Aug 15, 2025: Shares held short 1.28M
  • Aug 29, 2025: Shares held short 1.25M
  • Sep 15, 2025: Shares held short 1.33M
  • Sep 30, 2025: Shares held short 1.30M
  • Oct 15, 2025: Shares held short 1.31M
  • Oct 31, 2025: Shares held short 980.9K
  • Nov 14, 2025: Shares held short 1.07M
  • Nov 28, 2025: Shares held short 882.2K
  • Dec 15, 2025: Shares held short 859.1K
  • Dec 31, 2025: Shares held short 777.9K
  • Jan 15, 2026: Shares held short 741.6K
  • Jan 30, 2026: Shares held short 769.5K
  • Feb 13, 2026: Shares held short 811.6K
  • Feb 27, 2026: Shares held short 824.3K
  • Mar 13, 2026: Shares held short 806.6K
  • Mar 31, 2026: Shares held short 913.3K
  • Apr 15, 2026: Shares held short 930.6K
  • Apr 30, 2026: Shares held short 1.06M
  • May 15, 2026: Shares held short 623.4K
  • May 29, 2026: Shares held short 498.1K
  • Jun 15, 2026: Shares held short 450.6K
  • Jun 30, 2026: Shares held short 488.7K
  • Jul 15, 2026: Shares held short 609.2K
  • Jul 31, 2026: Shares held short 615.9K
  • Aug 14, 2026: Shares held short 532.1K
  • Aug 31, 2026: Shares held short 520.7K
  • Sep 15, 2026: Shares held short 545.0K
  • Sep 30, 2026: Shares held short 513.3K
  • Oct 15, 2026: Shares held short 487.5K

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading34.5% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 34.5% of the shares in the reported trades were short sales, against 32.9% in the 14 before.

Last 14 sessionsOct 30, 2026 – Nov 18, 2026
34.5%
The 14 beforeOct 12, 2026 – Oct 29, 2026
32.9%
Change
+1.6 pts
Short sales a dayon average, of 153.0K shares
52.7K
More than atof 3,656 US-listed companies, same days
10%
Median of alleight in ten from 34.4% to 63.7%
50.3%
  • Oct 12, 2026: Short sales 39.5%
  • Oct 13, 2026: Short sales 13.8%
  • Oct 14, 2026: Short sales 27.2%
  • Oct 15, 2026: Short sales 50.5%
  • Oct 16, 2026: Short sales 43.4%
  • Oct 19, 2026: Short sales 44.7%
  • Oct 20, 2026: Short sales 29.9%
  • Oct 21, 2026: Short sales 45.4%
  • Oct 22, 2026: Short sales 17.4%
  • Oct 23, 2026: Short sales 46.5%
  • Oct 26, 2026: Short sales 43.6%
  • Oct 27, 2026: Short sales 51.1%
  • Oct 28, 2026: Short sales 23%
  • Oct 29, 2026: Short sales 34.7%
  • Oct 30, 2026: Short sales 34.5%
  • Nov 2, 2026: Short sales 50.9%
  • Nov 3, 2026: Short sales 39.8%
  • Nov 4, 2026: Short sales 27%
  • Nov 5, 2026: Short sales 48.6%
  • Nov 6, 2026: Short sales 61.7%
  • Nov 9, 2026: Short sales 36.6%
  • Nov 10, 2026: Short sales 33.5%
  • Nov 11, 2026: Short sales 39%
  • Nov 12, 2026: Short sales 35%
  • Nov 13, 2026: Short sales 32.1%
  • Nov 16, 2026: Short sales 38.3%
  • Nov 17, 2026: Short sales 29.3%
  • Nov 18, 2026: Short sales 19.8%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

10.83M Insiders' shares31.41% Of the company
  • Southpoint GP, LLCTenPercentOwner
    Directly–
  • Southpoint Capital Advisors LLCTenPercentOwner
    Directly–
  • Southpoint Capital Advisors LPTenPercentOwner
    Directly–
  • Robert AndradeCHIEF FINANCIAL OFFICER
    Directly248.6K
  • Rosty RaykovOther
    Directly124.4K
  • Jeffrey S. HackmanChief Executive Officer
    Directly70.8K
  • Chris A RallisDirector
    Directly63.1K
  • Christiana Marie CioffiChief Strategy Officer
    Directly28.9K
  • Terry L EvansChief Commercial Officer
    Directly24.2K
  • Pierre Sargis SayadChief Medical Officer
    Directly13.7K
  • Marco Maria BrugheraDirector
    Directly–
  • Adrian HaighCHIEF OPERATING OFFICER
    Directly–

A lower bound: it counts only the 12 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

5 ETFs holding it0.07% The largest weight (IWC)
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.07%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.02%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.01%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.01%
  • VTIVanguard Total Stock Market Index Fund
    Weight in the fund0.00%

5 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

105 Managers, Q2 2026$175M Value of their positions
  • Q3 2025: Managers 84
  • Q4 2025: Managers 96
  • Q1 2026: Managers 91
  • Q2 2026: Managers 105

Institutional investors by quarter

The fund managers holding FENC, quarter by quarter, from Q3 2017 to Q2 2025, 32 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 105 managers held 16.31M shares, worth $175M. During the quarter 25 opened a position, 11 closed one, 42 added and 18 trimmed.

The largest holders, Q2 2026

  • Rosalind Advisors
    In the quarter+9.6%
  • AIGH Capital Management
    In the quarter+25%
  • Solas Capital Management
    In the quarter-24%
  • BlackRock
    In the quarter+26%
  • AWM Investment
    In the quarter+61%
  • Vanguard Capital Management
    In the quarter-6.4%
  • Prospect Capital Advisors
    In the quarter
  • State Street
    In the quarter+19%
  • Geode Capital Management
    In the quarter+8.3%
  • Jane Street Group
    In the quarter

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Fennec Pharmaceuticals's filings show?

Who buys and sells is one part of Fennec Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about FENC's shareholders

Didn't find what you were looking for?

Ask us
Have FENC's insiders bought or sold?

From Jun 1, 2026 to Nov 16, 2026 Fennec Pharmaceuticals's insiders bought 0 and sold $1.8M of shares on the market. 92% of the sales were under set 10b5-1 plans.

Which well-known managers hold FENC?

5 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $1.8M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.